arrow
M

Monia Marchetti

azienda ospedaliera universitaria ss antonio e biagio e c. arrigo
H指数:44
被引数:8,557

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

非适应证急性髓系白血病患者接受维奈克拉联合去甲基化药物的疗效:GIMEMA AML2320试验结果

2026-09-050
PRE
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study

赖氨酸特异性去甲基化酶1(LSD1)抑制剂bomedemstat在骨髓纤维化中的应用:一项1/2期研究的结果

2026-05-020
OAAI
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia

LSD1(赖氨酸特异性去甲基化酶1)抑制剂bomedemstat治疗原发性血小板增多症的2期研究

2026-03-030
OAAI
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis

欧洲白血病网络联盟(European LeukemiaNet)关于新药在骨髓纤维化中安全性和有效性评估的标准

2025-11-240
OAAI
Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B-Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts

定义并解决针对晚期侵袭性大B细胞淋巴瘤一线治疗当前未满足的医疗需求:来自意大利专家特别小组的视角

2025-11-030
OAAI
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design

探讨真性红细胞增多症的血栓栓塞危险因素:从现有证据到PROSPERO研究设计

2025-07-180
OA
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults
2024-03-145
OA
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

血液系统恶性肿瘤干细胞移植后移植物抗宿主病的预防和管理: 欧洲血液和骨髓移植学会的最新共识建议

2024-02-0131
PRE
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

通过新型冠状病毒肺炎大流行,多发性骨髓瘤和SARS-COV-2感染的生存率: epicovideha注册表的结果

2023-12-049
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
2023-06-292
OA